Parallax Volatility Advisers’s Alexion Pharmaceuticals ALXN Stock Holding History

Parallax Volatility Advisers’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,300	Closed	-$147K	–	3359
2020 Q3	$147K	Sell	1,300 -41,500	-97%	-$4.48M	﹤0.01%	2629
2020 Q2	$4.8M	Sell	42,800 -54,300	-56%	-$5.76M	0.01%	1095
2020 Q1	$8.72M	Buy	97,100 +58,800	+154%	+$5.77M	0.01%	658
2019 Q4	$4.14M	Buy	38,300 +26,400	+222%	+$2.82M	﹤0.01%	975
2019 Q3	$1.17M	Buy	+11,900	New	+$1.34M	﹤0.01%	1327
2018 Q4	–	Sell	-44,000	Closed	-$6.12M	–	4297
2018 Q3	$6.12M	Buy	+44,000	New	+$5.52M	0.01%	643
2018 Q2	–	Sell	-5,000	Closed	-$557K	–	3649
2018 Q1	$557K	Hold	5,000	–	–	﹤0.01%	1101
2017 Q4	$598K	Buy	+5,000	New	+$609K	﹤0.01%	1417
2015 Q4	–	Sell	-25,000	Closed	-$3.91M	–	4187
2015 Q3	$3.91M	Hold	25,000	–	–	0.01%	756
2015 Q2	$4.52M	Buy	+25,000	New	+$4.31M	0.01%	747
2014 Q2	–	Sell	-107,500	Closed	-$16.4M	–	4379
2014 Q1	$16.4M	Buy	+107,500	New	+$17.1M	0.1%	176

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Parallax Volatility Advisers's ALXN Position: Q4 2020 in Review

Parallax Volatility Advisers sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 1,181 shares — an estimated $135K sold.

Parallax Volatility Advisers first reported a position in ALXN in Q1 2014 and held it in 12 quarters. The position peaked at $6.46M in Q2 2020. 825 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

Parallax Volatility Advisers reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Parallax Volatility Advisers sold 1,181 Alexion Pharmaceuticals shares in Q4 2020, an estimated $135K.
Parallax Volatility Advisers first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 12 quarters.
Parallax Volatility Advisers's Alexion Pharmaceuticals position peaked at $6.46M in Q2 2020.
825 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Parallax Volatility Advisers's 13F filing for Q4 2020, filed 16 Feb 2021.